TLRY▼
Tilray Posts Record Fiscal 2026 Revenue but Stock Fails to Rally
Tilray Brands reported record fiscal 2026 revenue of about $915 million, up 11% year over year, yet its stock has not sustained a rally. Adjusted EBITDA rose 11% to $61.1 million and adjusted net income nearly doubled to $12.2 million, but adjusted earnings missed sell-side forecasts and GAAP net losses attributable to shareholders totaled $49.6 million, or negative 43 cents per share. For fiscal 2027, management guided adjusted EBITDA of $68 million to $75 million, though it is unclear whether this will translate into positive GAAP earnings. The company has reduced debt to effectively zero through dilutive debt-for-equity swaps, and cannabis now accounts for just 29% of overall sales amid diversification into alcoholic beverages and pharmaceutical distribution. Investors remain hesitant despite ongoing U.S. federal marijuana rescheduling efforts, with limited exposure to that catalyst.
The Motley Fool·3dRead more ▾
Tilray Brands expects to exceed $1 billion in annual revenue for fiscal 2027
Tilray Brands anticipates full-year revenue will exceed $1 billion for its fiscal 2027 year, a milestone that would mark a significant achievement for the company. The cannabis and beverage company reported net revenue of $915.5 million for fiscal 2026, an 11% increase from the prior year, and CEO Irwin Simon highlighted growth in European medical cannabis and the craft beer portfolio as key drivers. Tilray needs just over 9% revenue growth to reach the $1 billion target, which it aims to achieve through international expansion and further acquisitions in its beverage segment. Despite the top-line growth, the company posted a net loss of more than $105 million in fiscal 2026, and its stock has fallen 97% over the past five years amid concerns about consistent profitability.
The Motley Fool·16dRead more ▾
TLRY▼
Tilray to stop brewing at Terrapin facility in Georgia
Tilray Brands will cease beer production at its Terrapin facility in Athens, Georgia, effective 25 September, as part of a broader restructuring of its US brewing network. The company will shift brewing production to other facilities within its network while keeping the taproom, warehouse, and repack operations open at the current location. The move is part of 'Project 420', a programme aimed at boosting profitability through synergies, which has already included the closure and consolidation of several breweries, the sale of Atwater Brewery, and the rebranding of Revolver. For the fiscal year ended 31 May 2026, Tilray's beverage net revenue rose 6% to $254m, but gross profit fell 2% to $91.2m and gross margin narrowed to 36% from 39%.
Just Drinks·16dRead more ▾
TLRY▲impact 4
Vireo Growth to Acquire Planet 13 in All-Stock Deal as Cannabis and Psychedelic Sectors See Major Moves
Vireo Growth Inc. agreed to acquire Planet 13 Holdings Inc. in an all-stock transaction, one of several major developments in the cannabis and psychedelic sectors this week. Under the deal, each Planet 13 share will be exchanged for 0.015383618 of a Vireo subordinate voting share, representing a 16.6% premium to Planet 13's 20-day volume-weighted average share price as of July 24, 2026. The acquisition will add 36 dispensaries, three cultivation and production facilities, a distribution license, and a cannabis consumption lounge license to Vireo's portfolio, and following this and previously announced acquisitions, Vireo expects to operate approximately 265 dispensaries across 15 states. Separately, SNDL Inc. completed its acquisition of key assets from U.S. cannabis operator Parallel, gaining control of 56 retail locations and three cultivation and manufacturing facilities in Florida, Texas, and Massachusetts, and now supports a 249-store cannabis retail network. Tilray Brands reported record fiscal 2026 net revenue of $915.5 million, an 11% increase from the prior year, while its annual net loss narrowed sharply to $105.2 million from nearly $2.2 billion. In the psychedelic sector, Eli Lilly and Company announced a deal worth up to $3.8 billion to acquire AtaiBeckley Inc., including an upfront cash payment valuing the company at approximately $2.8 billion and an additional $1 billion in contingent milestone payments. Clearmind Medicine reported positive safety results from Part A of its Phase I/II trial of CMND-100 for Alcohol Use Disorder, with all 24 healthy volunteers completing treatment and no serious adverse events reported.
Yahoo Finance·24dRead more ▾
TLRY▲
Southern Glazer’s Closes Acquisition of Eagle Rock’s Colorado Operations
Southern Glazer’s Wine & Spirits has completed its acquisition of substantially all of the assets of Eagle Rock Distributing Co.’s Colorado operations. The deal brings Anheuser-Busch’s full Colorado product portfolio—including Michelob ULTRA, Busch Light, Budweiser, Bud Light, Cutwater Spirits, NÜTRL Vodka Seltzer, BeatBox Beverages, and Phorm Energy—as well as brands like Tilray Brands, Talking Rain, AriZona Beverages, Novamex, Essentia Water, Station 26 Brewing Co., Happy Dad, and Nestle under Southern Glazer’s distribution. Jeffrey Gerali, formerly Senior Commercial Director at Anheuser-Busch, has been named Senior Vice President, General Manager of Southern Glazer’s Beverage Company of Colorado, and Jason Charboneau becomes Senior Vice President, Sales for the Colorado unit. Eagle Rock will continue to operate its Georgia business in full.
Business Wire·26dRead more ▾
Tilray projects $68 million to $75 million in adjusted EBITDA for fiscal 2027
Tilray Brands guided for adjusted EBITDA between $68 million and $75 million in fiscal 2027, representing a double-digit increase from the prior year. The company reported record fiscal 2026 net revenue of $915.5 million, up 11%, and adjusted EBITDA of $61.1 million, which was impacted by approximately $2.3 million in unanticipated fuel surcharges. Net loss improved to $105.2 million, while adjusted net income rose 87% to $12.2 million. Management highlighted a near-zero net debt position, $235 million in cash and marketable securities, and the acquisition of BrewDog, which contributed $51.1 million in fourth-quarter beverage revenue. The company also announced it will begin brewing and selling Carlsberg brands in the U.S. starting January 1, 2027, and outlined priorities of margin expansion, efficiency, and innovation for the coming year.
Seeking Alpha·29dRead more ▾
TLRY▲
Revolver Brewing Expands Blood & Honey Brand into Whiskey, Gin and Vodka
Revolver Brewing, a subsidiary of Tilray Brands, announced its evolution into Revolver Beer & Spirits and the launch of Blood & Honey Whiskey, Gin, and Vodka. The new spirits line extends the Texas-born beer brand’s flagship Blood & Honey profile, featuring blood orange and raw, unfiltered Texas honey from Burleson's Honey. Each spirit is bottled at 80 proof and will be available exclusively in Texas starting today, with suggested retail prices of $29.99 for the whiskey, $23.99 for the gin, and $19.99 for the vodka.
GlobeNewswire·34dRead more ▾
TLRY▼
UK data watchdog assesses complaints over James Watt BrewDog buyback bid
The UK Information Commissioner's Office is assessing complaints that BrewDog co-founder James Watt may have breached data protection rules when contacting former shareholders about his bid to buy back the business. Watt launched an offer through his new venture Second Best to acquire BrewDog from US owner Tilray Brands, and reportedly emailed former Equity for Punks investors offering them the same stake in Second Best for free. Unnamed recipients told The Guardian they did not know how Watt obtained their contact details, raising GDPR concerns. Tilray Brands stated it did not acquire shareholder data as part of its purchase of BrewDog assets and had no involvement in the communications, while Alix Partners, which assisted the sale, declined to comment.
Just Drinks·37dRead more ▾
Tilray Brands faces pivotal earnings report on July 28
Tilray Brands is scheduled to report its fourth-quarter and full fiscal year 2026 results on July 28, with investors watching for continued revenue growth improvement and a reduction in massive annual losses. The Canadian cannabis producer’s quarterly year-over-year revenue growth has recently returned to double digits, but the company has posted annual losses exceeding $1 billion in two of the past three fiscal years due to non-cash expenses and impairment charges. Tilray’s stock has fallen 97% over the past five years and is trading near its 52-week low, making the upcoming report a potential catalyst for a rally if results beat expectations. However, the article cautions that a wait-and-see approach may be prudent given the company’s track record and ongoing uncertainty.
The Motley Fool·37dRead more ▾
TLRY▼
James Watt bids to buy back BrewDog from Tilray Brands
James Watt, the founder of BrewDog, has formally submitted an offer to buy back the UK business from US-listed Tilray Brands. The bid was made through his new venture Second Best, and Watt stated on LinkedIn that 43,000 equity punk investors have already joined the offer. If successful, registered punks would receive their BrewDog equity back for free, and Watt pledged to restore the Real Living Wage, bring back employee equity, and put the community at the heart of the business. Watt stepped down as BrewDog CEO two years ago, and Tilray had acquired BrewDog assets in the UK, Ireland, the US, and Australia earlier this year.
Just Drinks·42dRead more ▾
TLRY▲
Tilray Medical launches medical cannabis in Panama
Tilray Medical has commercially launched its first medical cannabis product in Panama, marking a significant step in its global expansion. The launch follows the shipment of Tilray Oral Solution CBD100 from the company’s EU-GMP-certified facilities in Portugal through a joint venture with Solana Life Group. The product will be distributed via Farmacias Arrocha, one of Panama’s leading pharmacy networks, and will be available to patients with a medical prescription. This move supports Panama’s medical cannabis framework under Law 242 of 2021 and recent regulatory advancements, including the introduction of a patient and caregiver identification system. Tilray Medical now serves patients in more than 20 countries across five continents.
GlobeNewswire·48dRead more ▾
TLRY▼
Tilray Brands stock falls 1.6%, underperforming broader market
Tilray Brands shares closed at $4.31, down 1.6% in the latest session, a steeper decline than the S&P 500's 0.45% loss. The stock has dropped 12.92% over the past month, while the Medical sector gained 6.33% and the S&P 500 rose 2.14%. The company is expected to report an adjusted loss of one cent per share for the upcoming quarter, a 105% decline from the prior-year period, on revenue of $268.17 million, up 19.43%. For the full year, consensus estimates call for a loss of 58 cents per share on revenue of $885.3 million. Analyst estimates have remained unchanged recently, and the stock carries a Zacks Rank of 3, or Hold.
Zacks Investment Research·50dRead more ▾
Tilray Brands Acquires HelloMD Corporation to Expand Medical Cannabis in Canada
Tilray Brands announced on June 29, 2026, that it is acquiring HelloMD Corporation, a digital healthcare and patient engagement platform, after gaining court approval as the successful bidder in HelloMD's formal sale process. The deal adds HelloMD's Canadian medical cannabis assets to Tilray's portfolio, creating what the company describes as a fully vertically integrated medical cannabis framework in Canada that links cultivation, clinical expertise, practitioner support, product access, and fulfillment. Tilray Canada President Blair MacNeil said the combination builds a more connected pathway for patients and healthcare practitioners, while HelloMD CEO Larry Lisser noted the platform has supported hundreds of thousands of patients through telehealth consultations and personalized guidance since its founding. Tilray also sees potential opportunities in adjacent wellness categories such as sleep support and pain management, where over-the-counter products represent a large market the company is not yet meaningfully part of. Financial terms of the transaction were not disclosed.
Insider Monkey·52dRead more ▾
TLRY
BrewDog CEO James Taylor exits after Tilray takeover
BrewDog CEO James Taylor has left the UK business following its acquisition by Tilray Brands. Taylor was promoted from CFO to chief executive in March last year and led the company through the ownership transition. Tilray completed deals for parts of BrewDog's UK, Ireland, US, and Australia operations earlier this year. The company will not directly replace Taylor; chief commercial officer Lauren Carrol now oversees day-to-day operations, reporting to Tilray's operations president Rajnish Ohri.
Just Drinks·56dRead more ▾
TLRY
Cannabis rescheduling hearing begins but prediction markets price low odds of 280E relief
The DEA's expedited administrative hearing on moving cannabis from Schedule I to Schedule III began June 29, 2026, with a conclusion targeted for mid-July, a move that would eliminate the Section 280E tax burden that forces U.S. cannabis operators to pay effective tax rates above 70%. The AdvisorShares Pure US Cannabis ETF has rallied 99.2% over the trailing year on rescheduling hopes but remains 81% below its September 2020 launch price. Prediction markets, however, price just an 18.5% probability of rescheduling by the end of July and 23.3% by year-end, with a contract for rescheduling by March 31 having already expired worthless. Canadian licensed producers Tilray Brands and Canopy Growth, which are not subject to 280E, have seen their shares fall 97.5% and 99.6% respectively from their peaks, mirroring the boom-and-bust pattern of prior reform cycles. For U.S. multi-state operators held in the AdvisorShares fund, 280E relief would be a structural unlock, shifting cash flows from the IRS to the income statement and narrowing the capital-raising discount, but timing has repeatedly destroyed capital in the sector.
24/7 Wall St.·57dRead more ▾
TLRY▲
BrewDog and Tilray Beer add Canada to £1 million bar tab promotion
BrewDog and Tilray Beer have added Canada to their £1 million bar tab promotion after Canada advanced to the next round of the world's biggest football tournament. The promotion will now activate if Canada, England or the United States reaches the final, with the bar tab opening on 20 July, the day after the final match. Fans wearing an eligible team jersey can claim up to two free pints per person at participating Tilray-owned BrewDog pubs in Scotland, England, Ireland and Las Vegas, excluding franchised locations, and at participating Tilray-owned brewpubs including SweetWater Brewing, 10 Barrel Brewing, Blue Point Brewery, Breckenridge Brewery, Montauk Brewing and Terrapin. The offer is on a first-come, first-served basis while funds and stocks last, and is subject to local laws and venue participation. The promotion is not affiliated with any international football governing body.
GlobeNewswire·58dRead more ▾
TLRY▼
Cronos Group Q1 Revenue Jumps 40% but Zacks Rates Stock a Sell
Cronos Group reported first-quarter 2026 net revenue of $45.2 million, a 40% year-over-year increase driven by higher cannabis flower sales in Israel, Canada, and other international markets. Gross profit rose 39% to $19.2 million, while its Canadian brands posted 18% retail sales growth, far outpacing the industry's 2% gain. Despite the strong quarter, Zacks Investment Research assigns Cronos a Zacks Rank of 4, or Sell, citing intense competition from peers such as Aurora Cannabis and Tilray Brands and caution about the pace at which strategic initiatives will translate into sustained earnings growth. The company's shares have risen more than 2% year to date, compared with a nearly 7% decline for the industry.
Zacks Investment Research·63dRead more ▾
TLRY▼
Tilray Brands shares fall 2.96%, underperforming broader market
Tilray Brands shares closed at $4.59, a decline of 2.96% that was steeper than the S&P 500's 0.37% loss. The stock has dropped 10.59% over the past month, underperforming both the Medical sector's 1.49% gain and the S&P 500's 2.02% advance. Ahead of its upcoming financial release, the Zacks Consensus Estimate projects an EPS of negative $0.01, down 105% from the prior-year quarter, on net sales of $268.17 million, a 19.43% increase. For the full year, analysts expect earnings of negative $0.58 per share and revenue of $885.3 million, representing changes of negative 680% and positive 7.79%, respectively. Tilray Brands currently carries a Zacks Rank of 3, or Hold, with no change in the consensus EPS estimate over the past month.
Zacks Investment Research·65dRead more ▾
Tilray Brands pivots to consumer goods but remains unprofitable
Tilray Brands is repositioning itself as a global lifestyle and consumer packaged goods company with operations in cannabis, beverages, and hemp-based foods, but it has never reported positive earnings as a public company. The company recently acquired craft brewer BrewDog out of administration and reported record revenues backed by 11% organic growth in the fiscal third quarter of 2026. With a market cap of roughly $500 million, Tilray faces execution risk as it integrates acquisitions across multiple countries. Most investors should watch from the sidelines until the revamped business proves sustainably profitable.
The Motley Fool·66dRead more ▾
TLRY▲
Hi*Ball Energy launches in the UK as a sugar-free functional energy water
Hi*Ball Energy, the sparkling energy water brand from Tilray Brands, has officially launched in the United Kingdom. The drink is now available via Amazon UK and BrewDog.com, with each 330ml can containing 100mg of natural caffeine, B vitamins, guarana, and ginseng, and no sugar, calories, or artificial sweeteners. The launch targets a growing consumer shift toward functional beverages, with 78% of UK energy drink consumers attracted to natural ingredients and 43% willing to try Hi*Ball as a more conscious alternative. Rajnish Ohri, President, International at Tilray Brands, said the UK debut is part of a broader strategy to expand the brand into additional European countries, the Middle East, Africa, and Asia-Pacific. The brand will showcase at the Barcode Festival on July 2, and the full range—Peach, Wild Berry, Lemon Lime, and Vanilla—is priced at £1.90 per can in 12-packs.
GlobeNewswire·69dRead more ▾